• Product NameRecombinant Human Hemofiltrate CC Chemokine-1/CCL14
• Host SpeciesE.coli
• Purification> 96 % by SDS-PAGE and HPLC analyses.
• Biological ActivityFully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using human monocytes is in a concentration of 5.0-20 ng/ml.
• EndotoxinLess than 1 EU/ug of rHuHCC-1/CCL14 as determined by LAL method.
• Alternative Names    HCC-1/HCC-3, NCC-2, Small-inducible Cytokine A14
• UniprotQ16627
• Gene ID6358
• Calculated MW Approximately 8.4 kDa, a single non-glycosylated polypeptide chain containing 72 amino acids.
• Target Sequence TESSSRGPYH PSECCFTYTT YKIPRQRIMD YYETNSQCSK PGIVFITKRG HSVCTNPSDK WVQDYIKDMK EN
• Formulation Lyophilized from a 0.2 um filtered concentrated solution in PBS.
• Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 ��C as supplied.- 1 month, 2 to 8 ��C under sterile conditions after reconstitution.- 3 months, -20 to -70 ��C under sterile conditions after reconstitution.

Human CCL14 is belonging to the CC chemokine family. It has two isoforms, CCL14a (HCC-1) and CCL14b (HCC-3). The sequence of HCC-3 differs from HCC-1 as follow: 27-27 R→ QTGGKPKVVKIQLKLVG. CCL14 was first isolated from the hemofiltrate of human patients with chronic renal failure. CCL14 promotes chemotaxis of T lymphocytes, monocytes and eosinophils, and inhibits infection of M-tropic human immunodeficiency virus type 1 and is a ligand for CCR1, CCR3 and CCR5. CCL14 is expressed constitutively in several normal tissues: spleen, liver, skeletal and heart muscle, gut, and bone marrow, present at high concentrations in plasma.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting